Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches 

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches
Chair & Presenter, Bradley J. Monk, MD, FACS, FACOG, Kathleen N. Moore, MD, MS, and Jessica Thomes Pepin, MD, discuss ovarian cancer in this CME/MOC/NCPD activity titled “When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/YWA865. CME/MOC/NCPD credit will be available until April 21, 2023.